Antonio Teixeira
Neurology · San Antonio, TXNPI 1639544851
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,500 of the $6,906 with a category attached, or 65.2%. Neurocrine Biosciences, Inc. accounts for 79.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $5,459 and has fallen 99.7% since, to $17 in 2025.
Across 18 payments — averaging $383.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$5K
- Lundbeck LLC$1K
- Teva Pharmaceuticals USA, Inc.$206
- AbbVie$55
- Otsuka Pharmaceutical Development & Commercialization, Inc.$17
Across 15 payments — averaging $2799.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38K
- E.r. Squibb & Sons, L.L.C.$4K
What the payments were for
- Consulting fees$4,50065%
- Speaking & faculty fees$1,17017%
- Travel & lodging$4627%
- Food & beverage$75811%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 13 | $5,459 |
| Lundbeck LLC | 1 | $1,170 |
| Teva Pharmaceuticals USA, Inc. | 2 | $206 |
| AbbVie | 1 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,906 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 35 | $608 |
| Mirtazapine | 22 | $368 |
| Trazodone Hcl | 27 | $281 |
| Divalproex Sodium | 14 | $271 |
| Donepezil Hcl | 23 | $169 |
| Escitalopram Oxalate | 17 | $137 |
| Clonazepam | 18 | $111 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $83 |
| Sertraline Hcl | 24 | $81 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Antonio
- Ann BassSan Antonio$1.7M
- Santiago RestrepoSan Antonio$532K
- Juan Ramirez CastanedaSan Antonio$456K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- Arash SalardiniSan Antonio$125K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.